<DOC>
	<DOCNO>NCT01821963</DOCNO>
	<brief_summary>The goal clinical research study learn antiviral combination telaprevir , pegylated Interferon Alfa 2a ( PegIFN alfa-2a ) ribavirin ( RBV ) prevent virus come back liver transplant . Telaprevir , PegIFN alfa-2a , RBV different antiviral drug work combination different stage HCV infection stop virus .</brief_summary>
	<brief_title>Telaprevir Plus Standard Care ( SOC ) HCV Associated Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , take telaprevir 3 time day . You take RVB mouth 2 time day . You receive PEGIFN alfa-2a injection skin 1 time week . Study Visits : On first day take study drug : - You eye exam perform study doctor . - You physical exam , include measurement vital sign ( blood pressure , heart rate , temperature , breathe rate ) . - Blood ( 2 teaspoon ) draw routine test check hepatitis virus . - You ask drug take side effect may . Every Week study : - You physical exam , include measurement vital sign . - Blood ( 2 teaspoon ) draw routine test check hepatitis C virus . If part blood sample leave Hepatitis C testing , store laboratory back-up sample , case original sample get lose . This sample may also use check Hepatitis C virus become resistant study drug . No extra blood drawn storage . - You ask drug take side effect may . - At Weeks 12 , 24 , 36 , 42 , urine collect check infection side effect drug . If become pregnant , urine pregnancy test every 4 week Length Treatment : You may continue receive antiviral therapy 48 week , long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study follow-up visit . Follow-Up Visits : Beginning day stop take antiviral therapy ( day transplantation , whichever come first ) , 24 week follow-up test perform . About 4 20 week last dose : - You physical exam , include measurement vital sign . - Blood ( 2 teaspoon ) draw routine test check hepatitis C virus . - You ask side effect may . - At week 4 , urine collect check infection side effect drug . This investigational study . Telaprevir , PegIFN alfa-2a , RBV FDA approve commercially available treatment HCV infection . The use drug prevent HCV infection investigational . Up 40 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Males female age ≥ 18 ≤ 70 year 2 . Detectable Hepatitis C Virus ribonucleic acid ( HCVRNA ) serum 3 . HCV genotype 1 infection 4 . ChildPughTurcotte ( CPT ) score &lt; 7 Model EndStage Liver Disease ( MELD ) score &lt; 18 5 . PegIFN alfa2a/RBVnaïve previously treat patient ( partial responder , null responder relapsers ) 6 . Hepatocellular carcinoma within transplant criterion United Network Organ Sharing ( UNOS ) Region IV : 1 . Single lesion 6 cm , 2 . Two three lesion large great 5 cm total tumor diameter great 9 cm 7 . Listed liver transplantation 8 . Willingness give write consent agree double contraception 1 . Decompensated cirrhosis 2 . Baseline platelet count less 35,000/µL 3 . Baseline hemoglobin level le 10 g/dL 4 . Baseline absolute neutrophil count less 750/mm3 5 . Baseline creatinine clearance &lt; 50 mL per min . 6 . Women positive pregnancy test baseline men whose female partner pregnant contemplate pregnancy 7 . Intolerance contraindication PegIFN alfa2a/RBV use per standard treatment guideline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Infection</keyword>
	<keyword>Hepatitis C Genotype 1 Infection</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>HCC</keyword>
	<keyword>Liver Transplantation</keyword>
	<keyword>Pegylated Interferon Alfa 2a</keyword>
	<keyword>PegIFN alfa-2a</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>RBV</keyword>
	<keyword>Telaprevir</keyword>
	<keyword>Incivek</keyword>
	<keyword>Antiviral drug</keyword>
</DOC>